Dopamine dysregulation syndrome in Parkinson's disease
Abstract
PURPOSE OF REVIEW: Dopamine replacement therapy in Parkinson's disease ameliorates motor symptoms. However, it has recently been recognized that a small sub-group of patients suffer motor and behavioural disturbances attributable to taking quantities of medication well beyond the dose required to treat their motor disabilities. This review examines the phenomenology of dopamine dysregulation syndrome in relation to the current understanding of basal ganglia function and its impact on long-term management. RECENT FINDINGS: Cortico-striato-thalamic circuits are implicated in the behavioural and motor disturbances associated with compulsive medication use in Parkinson's disease. Advances in understanding of the role of dopamine in psychostimulant addiction are important in helping to understand dopamine dysregulation. SUMMARY: Recognition of dopamine dysregulation syndrome and characterization of its phenomenology supports the notion that the medication used to treat Parkinson's disease can disrupt basal ganglia mediated motor and behavioural functioning. Refinement of clinical strategies to predict, identify and manage this syndrome will aid the future treatment of motor and non-motor complications of Parkinson's disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These symptoms called dopamine dysregulation syndrome or impulse control disorders are increasingly recognized in Parkinson's disease.
“These symptoms that together have been called dopamine dysregulation syndrome or impulse control disorders are increasingly recognized (Evans and Lees 2004).”
From The clinical symptoms of Parkinson's disease. (2016) · cites this paper as Evans and Lees 2004
Cites
Robinson, T. E., & Berridge, K. C. (2003) · Annual Review of Psychology · doi:10.1146/annurev.psych.54.101601.145237 · Cited by 1,509 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The clinical symptoms of Parkinson's disease.
Sveinbjornsdottir, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13691 · Cited by 1,410 · see citing works
From prediction error to incentive salience: mesolimbic computation of reward motivation.
Berridge, K. C. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.07990.x · Cited by 700 · see citing works
Compulsive drug use linked to sensitized ventral striatal dopamine transmission.
Evans, A. H., Pavese, N., Lawrence, A. D., Tai, Y. F., Appel, S., Doder, M., Brooks, D. J., Lees, A. J., & Piccini, P. (2006) · Annals of Neurology · doi:10.1002/ana.20822 · Cited by 473 · see citing works
Self-citationDopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder
Berk, M., Dodd, S., Kauer‐Sant’Anna, M., Malhi, G. S., Bourin, M., Kapczinski, F., & Norman, T. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01058.x · Cited by 396 · see citing works
Dopamine Dysregulation Syndrome: An Overview of its Epidemiology, Mechanisms and Management
OʼSullivan, S. S., Evans, A. H., & Lees, A. J. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00005 · Cited by 265 · see citing works
Self-citationCompulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward
Evans, A. H., Lawrence, A. D., Cresswell, S. A., Katzenschlager, R., & Lees, A. J. (2010) · Movement Disorders · doi:10.1002/mds.22898 · Cited by 51 · see citing works
Self-citation
- Authors
- Evans, A. H., & Lees, A. J.
- Affiliations
- National Hospital for Neurology and Neurosurgery (GB)
- Corresponding author
- Lees, Andrew J
- Venue
- Current Opinion in Neurology
- Published
- 2004-08
- Volume
- 17
- Issue
- 4
- Pages
- 393-398
- ISSN
- 1350-7540 (ISSN-L)
- OpenAlex
- W1979587906
- Cited by
- 257
- References
- 1
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 12 · 2023: 10 · 2022: 3 · 2021: 5 · 2020: 49 · 2019: 4 · 2018: 6 · 2017: 8 · 2016: 5 · 2015: 12 · 2014: 5 · 2013: 16 · 2012: 18
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- dopamine dysregulation syndrome, Parkinson's disease, dopamine replacement therapy, basal ganglia, stimulant use disorder, long-term management
- MeSH terms
- Animals, Antiparkinson Agents, Basal Ganglia, Mental Disorders, Dopamine, Humans, Parkinson Disease, Reward, Ventral Tegmental Area, Dopamine Agonists, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
